<?xml version="1.0" encoding="UTF-8"?><corpus source="HPRD50">  <document id="HPRD50.d0" origId="10373544" set="train">    <sentence charOffset="0-194" id="HPRD50.d0.s0" origId="10373544.1.1" text="Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III">      <entity charOffset="71-80" id="HPRD50.d0.s0.e0" origId="10" text="TFIIIC102" type="pm0125479" />      <entity charOffset="85-93" id="HPRD50.d0.s0.e1" origId="12" text="TFIIIC63" type="pm0100174" />      <entity charOffset="104-110" id="HPRD50.d0.s0.e2" origId="16" text="TFIIIC" type="pm0120026" />    </sentence>  </document>  <document id="HPRD50.d1" origId="10529171" set="train">    <sentence charOffset="0-102" id="HPRD50.d1.s0" origId="10529171.1.1" text="Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2">      <entity charOffset="34-64" id="HPRD50.d1.s0.e0" origId="8" text="monocyte chemotactic protein-1" type="pm0117207" />      <entity charOffset="98-102" id="HPRD50.d1.s0.e1" origId="15" text="CCR2" type="pm0111607" />      <interaction e1="HPRD50.d1.s0.e0" e2="HPRD50.d1.s0.e1" id="HPRD50.d1.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="103-269" id="HPRD50.d1.s1" origId="10529171.2.12" text="The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity">      <entity charOffset="29-34" id="HPRD50.d1.s1.e0" origId="6" text="MCP-1" type="pm0111607||pm0117207||pm0124628" />      <entity charOffset="93-99" id="HPRD50.d1.s1.e1" origId="16" text="RANTES" type="pm0105763" />      <entity charOffset="104-108" id="HPRD50.d1.s1.e2" origId="18" text="IL-8" type="pm0121149" />    </sentence>    <sentence charOffset="270-351" id="HPRD50.d1.s2" origId="10529171.2.13" text="It was previously shown that the N-terminus of CCR2 is critical for binding MCP-1">      <entity charOffset="47-51" id="HPRD50.d1.s2.e0" origId="9" text="CCR2" type="pm0111607" />      <entity charOffset="76-81" id="HPRD50.d1.s2.e1" origId="14" text="MCP-1" type="pm0111607||pm0117207||pm0124628" />      <interaction e1="HPRD50.d1.s2.e0" e2="HPRD50.d1.s2.e1" id="HPRD50.d1.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="352-474" id="HPRD50.d1.s3" origId="10529171.2.2" text="To identify the regions of MCP-1 that contact its receptor, CCR2, we substituted all surface-exposed residues with alanine">      <entity charOffset="27-32" id="HPRD50.d1.s3.e0" origId="6" text="MCP-1" type="pm0111607||pm0117207||pm0124628" />      <entity charOffset="60-64" id="HPRD50.d1.s3.e1" origId="12" text="CCR2" type="pm0111607" />      <interaction e1="HPRD50.d1.s3.e0" e2="HPRD50.d1.s3.e1" id="HPRD50.d1.s3.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d2" origId="10563789" set="train">    <sentence charOffset="0-151" id="HPRD50.d2.s0" origId="10563789.2.10" text="We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer">      <entity charOffset="94-101" id="HPRD50.d2.s0.e0" origId="19" text="CG beta" type="pm0125097" />      <entity charOffset="117-130" id="HPRD50.d2.s0.e1" origId="25" text="CG beta alpha" type="pm0125097" />      <entity charOffset="135-143" id="HPRD50.d2.s0.e2" origId="28" text="FSH beta" type="pm0104723" />    </sentence>    <sentence charOffset="152-363" id="HPRD50.d2.s1" origId="10563789.2.17" text="The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/CG beta subunit since CG single chain interacts with the monomeric FSH beta subunit and exhibits FSH activity">      <entity charOffset="102-109" id="HPRD50.d2.s1.e0" origId="21" text="CG beta" type="pm0125097" />      <entity charOffset="169-177" id="HPRD50.d2.s1.e1" origId="32" text="FSH beta" type="pm0104723" />    </sentence>    <sentence charOffset="364-612" id="HPRD50.d2.s2" origId="10563789.2.5" text="This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the LH beta or FSH beta subunits are different">      <entity charOffset="206-213" id="HPRD50.d2.s2.e0" origId="41" text="LH beta" type="pm0117290" />      <entity charOffset="217-225" id="HPRD50.d2.s2.e1" origId="44" text="FSH beta" type="pm0104723" />    </sentence>    <sentence charOffset="613-811" id="HPRD50.d2.s3" origId="10563789.2.7" text="Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively">      <entity charOffset="31-38" id="HPRD50.d2.s3.e0" origId="8" text="CG beta" type="pm0125097" />      <entity charOffset="42-50" id="HPRD50.d2.s3.e1" origId="11" text="FSH beta" type="pm0104723" />      <entity charOffset="154-167" id="HPRD50.d2.s3.e2" origId="31" text="CG beta alpha" type="pm0125097" />    </sentence>  </document>  <document id="HPRD50.d3" origId="10579793" set="train">    <sentence charOffset="0-115" id="HPRD50.d3.s0" origId="10579793.1.1" text="Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines">      <entity charOffset="0-13" id="HPRD50.d3.s0.e0" origId="1" text="Interleukin-6" type="pm0110911" />      <entity charOffset="24-53" id="HPRD50.d3.s0.e1" origId="4" text="phosphatidylinositol-3 kinase" type="pm0104655||pm0110290||pm0120114||pm0122783||pm0124741" />      <interaction e1="HPRD50.d3.s0.e0" e2="HPRD50.d3.s0.e1" id="HPRD50.d3.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="116-202" id="HPRD50.d3.s1" origId="10579793.2.6" text="RESULTS: Tyrosine phosphorylation of p85 is upregulated by IL-6 in both LNCaP and PC-3">      <entity charOffset="59-63" id="HPRD50.d3.s1.e0" origId="10" text="IL-6" type="pm0110911" />      <entity charOffset="82-86" id="HPRD50.d3.s1.e1" origId="15" text="PC-3" type="pm0107379||pm0107715||pm0114827" />    </sentence>    <sentence charOffset="203-305" id="HPRD50.d3.s2" origId="10579793.2.7" text="IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor">      <entity charOffset="0-4" id="HPRD50.d3.s2.e0" origId="1" text="IL-6" type="pm0110911" />      <entity charOffset="42-47" id="HPRD50.d3.s2.e1" origId="7" text="gp130" type="pm0113266||pm0122272" />      <entity charOffset="89-102" id="HPRD50.d3.s2.e2" origId="15" text="IL-6 receptor" type="pm0106299" />      <interaction e1="HPRD50.d3.s2.e0" e2="HPRD50.d3.s2.e1" id="HPRD50.d3.s2.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d4" origId="10736564" set="train">    <sentence charOffset="0-128" id="HPRD50.d4.s0" origId="10736564.2.5" text="In solution, FGFR4ed formed complexes with acidic FGF (FGF-1) and basic FGF (FGF-2), both in the presence and absence of heparin">      <entity charOffset="43-61" id="HPRD50.d4.s0.e0" origId="12" text="acidic FGF (FGF-1)" type="pm0124654" />      <entity charOffset="66-83" id="HPRD50.d4.s0.e1" origId="18" text="basic FGF (FGF-2)" type="pm0106166" />    </sentence>    <sentence charOffset="129-187" id="HPRD50.d4.s1" origId="10736564.2.6" text="Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2">      <entity charOffset="12-17" id="HPRD50.d4.s1.e0" origId="2" text="FGFR4" type="pm0119069" />      <entity charOffset="29-34" id="HPRD50.d4.s1.e1" origId="5" text="FGF-8" type="pm0118903" />      <entity charOffset="43-48" id="HPRD50.d4.s1.e2" origId="7" text="FGF-1" type="pm0124654" />      <entity charOffset="53-58" id="HPRD50.d4.s1.e3" origId="9" text="FGF-2" type="pm0106166" />      <interaction e1="HPRD50.d4.s1.e0" e2="HPRD50.d4.s1.e1" id="HPRD50.d4.s1.i0" type="PPI" />      <interaction e1="HPRD50.d4.s1.e0" e2="HPRD50.d4.s1.e2" id="HPRD50.d4.s1.i1" type="PPI" />      <interaction e1="HPRD50.d4.s1.e0" e2="HPRD50.d4.s1.e3" id="HPRD50.d4.s1.i2" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d5" origId="10835351" set="train">    <sentence charOffset="0-112" id="HPRD50.d5.s0" origId="10835351.1.1" text="Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1">      <entity charOffset="0-11" id="HPRD50.d5.s0.e0" origId="1" text="Cytohesin-1" type="pm0124251" />      <entity charOffset="107-112" id="HPRD50.d5.s0.e1" origId="13" text="LFA-1" type="pm0104657||pm0114514" />      <interaction e1="HPRD50.d5.s0.e0" e2="HPRD50.d5.s0.e1" id="HPRD50.d5.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="113-271" id="HPRD50.d5.s1" origId="10835351.2.2" text="Here we provide evidence of how cytohesin-1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for ARF GTPases, regulates cell adhesion">      <entity charOffset="32-43" id="HPRD50.d5.s1.e0" origId="7" text="cytohesin-1" type="pm0124251" />      <entity charOffset="122-125" id="HPRD50.d5.s1.e1" origId="20" text="ARF" type="pm0126206" />      <interaction e1="HPRD50.d5.s1.e0" e2="HPRD50.d5.s1.e1" id="HPRD50.d5.s1.i0" type="PPI" />    </sentence>    <sentence charOffset="272-477" id="HPRD50.d5.s2" origId="10835351.2.3" text="Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of LFA-1 depends on its interaction with cytohesin-1, unless the integrin is activated by exogenous divalent cations">      <entity charOffset="92-97" id="HPRD50.d5.s2.e0" origId="14" text="LFA-1" type="pm0104657||pm0114514" />      <entity charOffset="130-141" id="HPRD50.d5.s2.e1" origId="20" text="cytohesin-1" type="pm0124251" />      <interaction e1="HPRD50.d5.s2.e0" e2="HPRD50.d5.s2.e1" id="HPRD50.d5.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="478-635" id="HPRD50.d5.s3" origId="10835351.2.4" text="Secondly, cytohesin-1 induces expression of an extracellular activation epitope of LFA-1, and the exchange factor function is not essential for this activity">      <entity charOffset="10-21" id="HPRD50.d5.s3.e0" origId="3" text="cytohesin-1" type="pm0124251" />      <entity charOffset="83-88" id="HPRD50.d5.s3.e1" origId="12" text="LFA-1" type="pm0104657||pm0114514" />      <interaction e1="HPRD50.d5.s3.e0" e2="HPRD50.d5.s3.e1" id="HPRD50.d5.s3.i0" type="PPI" />    </sentence>    <sentence charOffset="636-834" id="HPRD50.d5.s4" origId="10835351.2.5" text="In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a cytohesin-1 mutant, which fails to catalyze ARF GDP-GTP exchange in vitro">      <entity charOffset="125-136" id="HPRD50.d5.s4.e0" origId="20" text="cytohesin-1" type="pm0124251" />      <entity charOffset="169-172" id="HPRD50.d5.s4.e1" origId="27" text="ARF" type="pm0126206" />      <interaction e1="HPRD50.d5.s4.e0" e2="HPRD50.d5.s4.e1" id="HPRD50.d5.s4.i0" type="PPI" />    </sentence>    <sentence charOffset="835-1003" id="HPRD50.d5.s5" origId="10835351.2.6" text="Thus, cytohesin-1 is involved in the activation of LFA-1, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity">      <entity charOffset="6-17" id="HPRD50.d5.s5.e0" origId="3" text="cytohesin-1" type="pm0124251" />      <entity charOffset="51-56" id="HPRD50.d5.s5.e1" origId="10" text="LFA-1" type="pm0104657||pm0114514" />      <interaction e1="HPRD50.d5.s5.e0" e2="HPRD50.d5.s5.e1" id="HPRD50.d5.s5.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d7" origId="10930400" set="train">    <sentence charOffset="0-154" id="HPRD50.d7.s0" origId="10930400.1.1" text="Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2">      <entity charOffset="62-110" id="HPRD50.d7.s0.e0" origId="12" text="peroxisome proliferator-activated receptor gamma" type="pm0103183" />      <entity charOffset="150-154" id="HPRD50.d7.s0.e1" origId="19" text="NRF2" type="pm0105918||pm0123857" />      <interaction e1="HPRD50.d7.s0.e0" e2="HPRD50.d7.s0.e1" id="HPRD50.d7.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="155-379" id="HPRD50.d7.s1" origId="10930400.2.5" text="Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 (NF-E2)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene">      <entity charOffset="136-141" id="HPRD50.d7.s1.e0" origId="23" text="NF-E2" type="pm0120477" />      <entity charOffset="143-147" id="HPRD50.d7.s1.e1" origId="26" text="AP-1" type="pm0103880" />    </sentence>    <sentence charOffset="380-644" id="HPRD50.d7.s2" origId="10930400.2.6" text="By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)">      <entity charOffset="50-55" id="HPRD50.d7.s2.e0" origId="8" text="NF-E2" type="pm0120477" />      <entity charOffset="56-60" id="HPRD50.d7.s2.e1" origId="10" text="AP-1" type="pm0103880" />      <entity charOffset="235-239" id="HPRD50.d7.s2.e2" origId="37" text="NRF2" type="pm0105918||pm0123857" />      <entity charOffset="241-263" id="HPRD50.d7.s2.e3" origId="41" text="NF-E2-related factor 2" type="pm0105918" />    </sentence>    <sentence charOffset="645-760" id="HPRD50.d7.s3" origId="10930400.2.9" text="Finally, a direct interaction between PPARgamma and NRF2 was confirmed by glutathione S-transferase pull-down assay">      <entity charOffset="52-56" id="HPRD50.d7.s3.e0" origId="9" text="NRF2" type="pm0105918||pm0123857" />      <entity charOffset="74-99" id="HPRD50.d7.s3.e1" origId="14" text="glutathione S-transferase" type="pm0116848" />    </sentence>  </document>  <document id="HPRD50.d8" origId="10995457" set="train">    <sentence charOffset="0-206" id="HPRD50.d8.s0" origId="10995457.2.3" text="By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to Hsp90 and amino acid residues 327-340 of Hsp90beta were involved in the binding to Akt">      <entity charOffset="120-125" id="HPRD50.d8.s0.e0" origId="21" text="Hsp90" type="pm0114253||pm0121838" />      <entity charOffset="161-170" id="HPRD50.d8.s0.e1" origId="28" text="Hsp90beta" type="pm0121838" />    </sentence>  </document>  <document id="HPRD50.d9" origId="11171101" set="train">    <sentence charOffset="0-114" id="HPRD50.d9.s0" origId="11171101.2.2" text="Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)">      <entity charOffset="62-70" id="HPRD50.d9.s0.e0" origId="12" text="KIAA1427" type="pm0110335" />      <entity charOffset="94-97" id="HPRD50.d9.s0.e1" origId="17" text="Syt" type="pm0109470||pm0116152" />      <entity charOffset="105-113" id="HPRD50.d9.s0.e2" origId="21" text="Syt XIII" type="pm0110335" />    </sentence>    <sentence charOffset="115-305" id="HPRD50.d9.s1" origId="11171101.2.3" text="Subcellular fractionation and antibody-uptake experiments indicate that Syt XIII is indeed a type-I membrane protein, but, unlike other Syt isoforms, lacks an N-terminal extracellular domain">      <entity charOffset="72-80" id="HPRD50.d9.s1.e0" origId="9" text="Syt XIII" type="pm0110335" />      <entity charOffset="136-139" id="HPRD50.d9.s1.e1" origId="21" text="Syt" type="pm0109470||pm0116152" />    </sentence>  </document>  <document id="HPRD50.d11" origId="11313349" set="train">    <sentence charOffset="0-155" id="HPRD50.d11.s0" origId="11313349.1.1" text="Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells">      <entity charOffset="51-58" id="HPRD50.d11.s0.e0" origId="9" text="ADAM 12" type="pm0118647" />      <entity charOffset="92-100" id="HPRD50.d11.s0.e1" origId="17" text="p85alpha" type="pm0124741" />      <entity charOffset="111-140" id="HPRD50.d11.s0.e2" origId="20" text="phosphatidylinositol 3-kinase" type="pm0104655||pm0110290||pm0120114||pm0122783||pm0124741" />      <interaction e1="HPRD50.d11.s0.e0" e2="HPRD50.d11.s0.e1" id="HPRD50.d11.s0.i0" type="PPI" />      <interaction e1="HPRD50.d11.s0.e0" e2="HPRD50.d11.s0.e2" id="HPRD50.d11.s0.i1" type="PPI" />      <interaction e1="HPRD50.d11.s0.e1" e2="HPRD50.d11.s0.e2" id="HPRD50.d11.s0.i2" type="PPI" />    </sentence>    <sentence charOffset="156-334" id="HPRD50.d11.s1" origId="11313349.2.5" text="This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85alpha, activates PI 3-kinase by mediating its recruitment to the membrane">      <entity charOffset="33-40" id="HPRD50.d11.s1.e0" origId="6" text="ADAM 12" type="pm0118647" />      <entity charOffset="102-110" id="HPRD50.d11.s1.e1" origId="19" text="p85alpha" type="pm0124741" />      <interaction e1="HPRD50.d11.s1.e0" e2="HPRD50.d11.s1.e1" id="HPRD50.d11.s1.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d12" origId="11779129" set="train">    <sentence charOffset="0-102" id="HPRD50.d12.s0" origId="11779129.1.1" text="AP180 binds to the C-terminal SH2 domain of phospholipase C-gamma1 and inhibits its enzymatic activity">      <entity charOffset="0-5" id="HPRD50.d12.s0.e0" origId="1" text="AP180" type="pm0106306" />      <entity charOffset="44-66" id="HPRD50.d12.s0.e1" origId="10" text="phospholipase C-gamma1" type="pm0126499" />      <interaction e1="HPRD50.d12.s0.e0" e2="HPRD50.d12.s0.e1" id="HPRD50.d12.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="103-357" id="HPRD50.d12.s1" origId="11779129.2.4" text="In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner">      <entity charOffset="57-66" id="HPRD50.d12.s1.e0" origId="11" text="PLCgamma1" type="pm0126499" />      <entity charOffset="72-77" id="HPRD50.d12.s1.e1" origId="13" text="AP180" type="pm0106306" />      <entity charOffset="176-185" id="HPRD50.d12.s1.e2" origId="30" text="PLCgamma1" type="pm0126499" />      <interaction e1="HPRD50.d12.s1.e0" e2="HPRD50.d12.s1.e1" id="HPRD50.d12.s1.i0" type="PPI" />      <interaction e1="HPRD50.d12.s1.e1" e2="HPRD50.d12.s1.e2" id="HPRD50.d12.s1.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d13" origId="11940666" set="train">    <sentence charOffset="0-83" id="HPRD50.d13.s0" origId="11940666.2.5" text="Here we demonstrate colocalization and direct interaction between CLIP-170 and LIS1">      <entity charOffset="66-74" id="HPRD50.d13.s0.e0" origId="9" text="CLIP-170" type="pm0124985" />      <entity charOffset="79-83" id="HPRD50.d13.s0.e1" origId="11" text="LIS1" type="pm0110467" />      <interaction e1="HPRD50.d13.s0.e0" e2="HPRD50.d13.s0.e1" id="HPRD50.d13.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="84-299" id="HPRD50.d13.s1" origId="11940666.2.7" text="Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs">      <entity charOffset="18-26" id="HPRD50.d13.s1.e0" origId="3" text="CLIP-170" type="pm0124985" />      <entity charOffset="80-92" id="HPRD50.d13.s1.e1" origId="12" text="phospho-LIS1" type="phospho-pm0110467" />      <entity charOffset="158-166" id="HPRD50.d13.s1.e2" origId="24" text="CLIP-170" type="pm0124985" />      <entity charOffset="171-175" id="HPRD50.d13.s1.e3" origId="26" text="LIS1" type="pm0110467" />      <interaction e1="HPRD50.d13.s1.e0" e2="HPRD50.d13.s1.e1" id="HPRD50.d13.s1.i0" type="PPI" />    </sentence>    <sentence charOffset="300-467" id="HPRD50.d13.s2" origId="11940666.2.8" text="This work suggests that LIS1 is a regulated adapter between CLIP-170 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics">      <entity charOffset="24-28" id="HPRD50.d13.s2.e0" origId="5" text="LIS1" type="pm0110467" />      <entity charOffset="60-68" id="HPRD50.d13.s2.e1" origId="11" text="CLIP-170" type="pm0124985" />      <interaction e1="HPRD50.d13.s2.e0" e2="HPRD50.d13.s2.e1" id="HPRD50.d13.s2.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d14" origId="11994745" set="train">    <sentence charOffset="0-56" id="HPRD50.d14.s0" origId="11994745.1.1" text="Megalin and cubilin: multifunctional endocytic receptors">      <entity charOffset="0-7" id="HPRD50.d14.s0.e0" origId="1" text="Megalin" type="pm0100604" />      <entity charOffset="12-19" id="HPRD50.d14.s0.e1" origId="3" text="cubilin" type="pm0100963" />    </sentence>    <sentence charOffset="57-165" id="HPRD50.d14.s1" origId="11994745.2.2" text="Megalin and cubilin are two structurally different endocytic receptors that interact to serve such functions">      <entity charOffset="0-7" id="HPRD50.d14.s1.e0" origId="1" text="Megalin" type="pm0100604" />      <entity charOffset="12-19" id="HPRD50.d14.s1.e1" origId="3" text="cubilin" type="pm0100963" />      <interaction e1="HPRD50.d14.s1.e0" e2="HPRD50.d14.s1.e1" id="HPRD50.d14.s1.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d16" origId="12124778" set="train">    <sentence charOffset="0-132" id="HPRD50.d16.s0" origId="12124778.1.1" text="GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress">      <entity charOffset="0-7" id="HPRD50.d16.s0.e0" origId="1" text="GADD45b" type="pm0114403" />      <entity charOffset="12-19" id="HPRD50.d16.s0.e1" origId="3" text="GADD45g" type="pm0116690" />      <entity charOffset="24-28" id="HPRD50.d16.s0.e2" origId="5" text="cdc2" type="pm0113152" />      <interaction e1="HPRD50.d16.s0.e0" e2="HPRD50.d16.s0.e2" id="HPRD50.d16.s0.i0" type="PPI" />      <interaction e1="HPRD50.d16.s0.e1" e2="HPRD50.d16.s0.e2" id="HPRD50.d16.s0.i1" type="PPI" />    </sentence>    <sentence charOffset="133-358" id="HPRD50.d16.s1" origId="12124778.2.1" text="Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis">      <entity charOffset="0-7" id="HPRD50.d16.s1.e0" origId="1" text="Gadd45a" type="pm0112301" />      <entity charOffset="9-15" id="HPRD50.d16.s1.e1" origId="3" text="Gadd45" type="pm0112301" />      <entity charOffset="18-25" id="HPRD50.d16.s1.e2" origId="6" text="Gadd45b" type="pm0114403" />      <entity charOffset="27-33" id="HPRD50.d16.s1.e3" origId="8" text="MyD118" type="pm0114403" />      <entity charOffset="40-47" id="HPRD50.d16.s1.e4" origId="12" text="Gadd45g" type="pm0116690" />      <entity charOffset="49-52" id="HPRD50.d16.s1.e5" origId="14" text="CR6" type="pm0102392||pm0116690" />    </sentence>    <sentence charOffset="359-465" id="HPRD50.d16.s2" origId="12124778.2.3" text="Recent evidence has implicated Gadd45a in inhibition of cdc2/cyclinB1 kinase and in G2/M cell cycle arrest">      <entity charOffset="31-38" id="HPRD50.d16.s2.e0" origId="5" text="Gadd45a" type="pm0112301" />      <entity charOffset="56-60" id="HPRD50.d16.s2.e1" origId="9" text="cdc2" type="pm0113152" />      <interaction e1="HPRD50.d16.s2.e0" e2="HPRD50.d16.s2.e1" id="HPRD50.d16.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="466-624" id="HPRD50.d16.s3" origId="12124778.2.4" text="Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established">      <entity charOffset="13-20" id="HPRD50.d16.s3.e0" origId="4" text="Gadd45b" type="pm0114403" />      <entity charOffset="28-35" id="HPRD50.d16.s3.e1" origId="6" text="Gadd45g" type="pm0116690" />      <entity charOffset="62-66" id="HPRD50.d16.s3.e2" origId="11" text="cdc2" type="pm0113152" />      <interaction e1="HPRD50.d16.s3.e0" e2="HPRD50.d16.s3.e2" id="HPRD50.d16.s3.i0" type="PPI" />      <interaction e1="HPRD50.d16.s3.e1" e2="HPRD50.d16.s3.e2" id="HPRD50.d16.s3.i1" type="PPI" />    </sentence>    <sentence charOffset="625-787" id="HPRD50.d16.s4" origId="12124778.2.5" text="In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo">      <entity charOffset="27-34" id="HPRD50.d16.s4.e0" origId="8" text="Gadd45b" type="pm0114403" />      <entity charOffset="39-46" id="HPRD50.d16.s4.e1" origId="10" text="Gadd45g" type="pm0116690" />      <entity charOffset="78-82" id="HPRD50.d16.s4.e2" origId="15" text="Cdk1" type="pm0113152" />      <interaction e1="HPRD50.d16.s4.e0" e2="HPRD50.d16.s4.e2" id="HPRD50.d16.s4.i0" type="PPI" />      <interaction e1="HPRD50.d16.s4.e1" e2="HPRD50.d16.s4.e2" id="HPRD50.d16.s4.i1" type="PPI" />    </sentence>    <sentence charOffset="788-975" id="HPRD50.d16.s5" origId="12124778.2.6" text="Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex">      <entity charOffset="33-40" id="HPRD50.d16.s5.e0" origId="7" text="Gadd45b" type="pm0114403" />      <entity charOffset="45-52" id="HPRD50.d16.s5.e1" origId="9" text="Gadd45g" type="pm0116690" />      <entity charOffset="65-72" id="HPRD50.d16.s5.e2" origId="14" text="GADD45a" type="pm0112301" />      <entity charOffset="93-97" id="HPRD50.d16.s5.e3" origId="19" text="Cdk1" type="pm0113152" />      <entity charOffset="166-170" id="HPRD50.d16.s5.e4" origId="32" text="Cdk1" type="pm0113152" />      <interaction e1="HPRD50.d16.s5.e0" e2="HPRD50.d16.s5.e3" id="HPRD50.d16.s5.i0" type="PPI" />      <interaction e1="HPRD50.d16.s5.e0" e2="HPRD50.d16.s5.e4" id="HPRD50.d16.s5.i1" type="PPI" />      <interaction e1="HPRD50.d16.s5.e1" e2="HPRD50.d16.s5.e3" id="HPRD50.d16.s5.i2" type="PPI" />      <interaction e1="HPRD50.d16.s5.e1" e2="HPRD50.d16.s5.e4" id="HPRD50.d16.s5.i3" type="PPI" />      <interaction e1="HPRD50.d16.s5.e2" e2="HPRD50.d16.s5.e3" id="HPRD50.d16.s5.i4" type="PPI" />      <interaction e1="HPRD50.d16.s5.e2" e2="HPRD50.d16.s5.e4" id="HPRD50.d16.s5.i5" type="PPI" />    </sentence>    <sentence charOffset="976-1134" id="HPRD50.d16.s6" origId="12124778.2.7" text="Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex">      <entity charOffset="14-18" id="HPRD50.d16.s6.e0" origId="3" text="Cdk1" type="pm0113152" />      <entity charOffset="47-54" id="HPRD50.d16.s6.e1" origId="9" text="Gadd45b" type="pm0114403" />      <entity charOffset="59-66" id="HPRD50.d16.s6.e2" origId="11" text="Gadd45a" type="pm0112301" />      <entity charOffset="123-130" id="HPRD50.d16.s6.e3" origId="22" text="Gadd45g" type="pm0116690" />      <interaction e1="HPRD50.d16.s6.e0" e2="HPRD50.d16.s6.e1" id="HPRD50.d16.s6.i0" type="PPI" />      <interaction e1="HPRD50.d16.s6.e0" e2="HPRD50.d16.s6.e2" id="HPRD50.d16.s6.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d18" origId="12370829" set="train">    <sentence charOffset="0-85" id="HPRD50.d18.s0" origId="12370829.1.1" text="The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)">      <entity charOffset="18-55" id="HPRD50.d18.s0.e0" origId="6" text="receptor protein tyrosine phosphatase" type="pm0104157" />      <entity charOffset="56-60" id="HPRD50.d18.s0.e1" origId="7" text="DEP1" type="pm0115917" />      <entity charOffset="76-85" id="HPRD50.d18.s0.e2" origId="13" text="p120(ctn)" type="pm0101886" />      <interaction e1="HPRD50.d18.s0.e0" e2="HPRD50.d18.s0.e2" id="HPRD50.d18.s0.i0" type="PPI" />      <interaction e1="HPRD50.d18.s0.e1" e2="HPRD50.d18.s0.e2" id="HPRD50.d18.s0.i1" type="PPI" />    </sentence>    <sentence charOffset="86-260" id="HPRD50.d18.s1" origId="12370829.2.1" text="The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes">      <entity charOffset="4-46" id="HPRD50.d18.s1.e0" origId="5" text="receptor-like protein tyrosine phosphatase" type="pm0104157" />      <entity charOffset="47-51" id="HPRD50.d18.s1.e1" origId="6" text="DEP1" type="pm0115917" />      <entity charOffset="67-72" id="HPRD50.d18.s1.e2" origId="11" text="CD148" type="pm0115917" />    </sentence>    <sentence charOffset="261-368" id="HPRD50.d18.s2" origId="12370829.2.5" text="DEP1 also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin">      <entity charOffset="0-4" id="HPRD50.d18.s2.e0" origId="1" text="DEP1" type="pm0115917" />      <entity charOffset="77-89" id="HPRD50.d18.s2.e1" origId="13" text="beta-catenin" type="pm0126674" />      <interaction e1="HPRD50.d18.s2.e0" e2="HPRD50.d18.s2.e1" id="HPRD50.d18.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="369-527" id="HPRD50.d18.s3" origId="12370829.2.6" text="The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression">      <entity charOffset="21-30" id="HPRD50.d18.s3.e0" origId="7" text="p120(ctn)" type="pm0101886" />      <entity charOffset="137-147" id="HPRD50.d18.s3.e1" origId="26" text="E-cadherin" type="pm0115783" />    </sentence>    <sentence charOffset="528-749" id="HPRD50.d18.s4" origId="12370829.2.7" text="Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific">      <entity charOffset="47-55" id="HPRD50.d18.s4.e0" origId="7" text="PTP-PEST" type="pm0117107" />      <entity charOffset="57-61" id="HPRD50.d18.s4.e1" origId="9" text="CD45" type="pm0110536" />      <entity charOffset="185-189" id="HPRD50.d18.s4.e2" origId="31" text="DEP1" type="pm0115917" />    </sentence>  </document>  <document id="HPRD50.d19" origId="12371907" set="train">    <sentence charOffset="0-188" id="HPRD50.d19.s0" origId="12371907.1.1" text="p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor">      <entity charOffset="0-4" id="HPRD50.d19.s0.e0" origId="1" text="p300" type="pm0126787" />      <entity charOffset="5-42" id="HPRD50.d19.s0.e1" origId="3" text="cAMP-response-element-binding-protein" type="pm0100874" />      <entity charOffset="45-49" id="HPRD50.d19.s0.e2" origId="6" text="CREB" type="pm0100874" />      <entity charOffset="133-138" id="HPRD50.d19.s0.e3" origId="22" text="MEF2A" type="pm0122391" />      <interaction e1="HPRD50.d19.s0.e0" e2="HPRD50.d19.s0.e3" id="HPRD50.d19.s0.i0" type="PPI" />      <interaction e1="HPRD50.d19.s0.e1" e2="HPRD50.d19.s0.e3" id="HPRD50.d19.s0.i1" type="PPI" />      <interaction e1="HPRD50.d19.s0.e2" e2="HPRD50.d19.s0.e3" id="HPRD50.d19.s0.i2" type="PPI" />    </sentence>    <sentence charOffset="189-361" id="HPRD50.d19.s1" origId="12371907.2.3" text="p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters">      <entity charOffset="0-4" id="HPRD50.d19.s1.e0" origId="1" text="p300" type="pm0126787" />      <entity charOffset="5-42" id="HPRD50.d19.s1.e1" origId="3" text="cAMP-response-element-binding-protein" type="pm0100874" />      <entity charOffset="45-49" id="HPRD50.d19.s1.e2" origId="6" text="CREB" type="pm0100874" />    </sentence>    <sentence charOffset="362-557" id="HPRD50.d19.s2" origId="12371907.2.7" text="Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex">      <entity charOffset="56-60" id="HPRD50.d19.s2.e0" origId="10" text="p300" type="pm0126787" />      <entity charOffset="105-110" id="HPRD50.d19.s2.e1" origId="19" text="MEF2A" type="pm0122391" />      <entity charOffset="158-163" id="HPRD50.d19.s2.e2" origId="30" text="MEF2A" type="pm0122391" />      <entity charOffset="168-172" id="HPRD50.d19.s2.e3" origId="32" text="p300" type="pm0126787" />      <interaction e1="HPRD50.d19.s2.e0" e2="HPRD50.d19.s2.e1" id="HPRD50.d19.s2.i0" type="PPI" />      <interaction e1="HPRD50.d19.s2.e2" e2="HPRD50.d19.s2.e3" id="HPRD50.d19.s2.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d20" origId="12655004" set="train">    <sentence charOffset="0-146" id="HPRD50.d20.s0" origId="12655004.1.1" text="The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes">      <entity charOffset="10-14" id="HPRD50.d20.s0.e0" origId="3" text="Imp3" type="pm0100548||pm0102353||pm0121765" />      <entity charOffset="19-23" id="HPRD50.d20.s0.e1" origId="5" text="Imp4" type="pm0104160||pm0117832" />      <entity charOffset="102-108" id="HPRD50.d20.s0.e2" origId="20" text="snoRNA" type="pm0114346" />      <interaction e1="HPRD50.d20.s0.e0" e2="HPRD50.d20.s0.e1" id="HPRD50.d20.s0.i0" type="PPI" />      <interaction e1="HPRD50.d20.s0.e0" e2="HPRD50.d20.s0.e2" id="HPRD50.d20.s0.i1" type="PPI" />      <interaction e1="HPRD50.d20.s0.e1" e2="HPRD50.d20.s0.e2" id="HPRD50.d20.s0.i2" type="PPI" />    </sentence>    <sentence charOffset="147-262" id="HPRD50.d20.s1" origId="12655004.2.3" text="We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4">      <entity charOffset="102-106" id="HPRD50.d20.s1.e0" origId="17" text="Imp3" type="pm0100548||pm0102353||pm0121765" />      <entity charOffset="111-115" id="HPRD50.d20.s1.e1" origId="19" text="Imp4" type="pm0104160||pm0117832" />    </sentence>    <sentence charOffset="263-520" id="HPRD50.d20.s2" origId="12655004.2.5" text="The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved">      <entity charOffset="75-79" id="HPRD50.d20.s2.e0" origId="13" text="Imp4" type="pm0104160||pm0117832" />      <entity charOffset="87-91" id="HPRD50.d20.s2.e1" origId="16" text="Imp3" type="pm0100548||pm0102353||pm0121765" />      <entity charOffset="202-206" id="HPRD50.d20.s2.e2" origId="35" text="Imp3" type="pm0100548||pm0102353||pm0121765" />    </sentence>    <sentence charOffset="521-727" id="HPRD50.d20.s3" origId="12655004.2.6" text="The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes">      <entity charOffset="104-108" id="HPRD50.d20.s3.e0" origId="18" text="Imp3" type="pm0100548||pm0102353||pm0121765" />      <entity charOffset="113-117" id="HPRD50.d20.s3.e1" origId="20" text="Imp4" type="pm0104160||pm0117832" />      <entity charOffset="162-168" id="HPRD50.d20.s3.e2" origId="27" text="snoRNA" type="pm0114346" />      <interaction e1="HPRD50.d20.s3.e0" e2="HPRD50.d20.s3.e2" id="HPRD50.d20.s3.i0" type="PPI" />      <interaction e1="HPRD50.d20.s3.e1" e2="HPRD50.d20.s3.e2" id="HPRD50.d20.s3.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d21" origId="12690115" set="train">    <sentence charOffset="0-154" id="HPRD50.d21.s0" origId="12690115.2.1" text="In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system">      <entity charOffset="90-93" id="HPRD50.d21.s0.e0" origId="15" text="CB1" type="pm0109721" />      <entity charOffset="102-119" id="HPRD50.d21.s0.e1" origId="20" text="orexin 1 receptor" type="pm0111533" />      <entity charOffset="121-125" id="HPRD50.d21.s0.e2" origId="22" text="OX1R" type="pm0111533" />      <interaction e1="HPRD50.d21.s0.e0" e2="HPRD50.d21.s0.e1" id="HPRD50.d21.s0.i0" type="PPI" />      <interaction e1="HPRD50.d21.s0.e0" e2="HPRD50.d21.s0.e2" id="HPRD50.d21.s0.i1" type="PPI" />    </sentence>    <sentence charOffset="155-259" id="HPRD50.d21.s1" origId="12690115.2.4" text="In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R">      <entity charOffset="15-19" id="HPRD50.d21.s1.e0" origId="4" text="OX1R" type="pm0111533" />      <entity charOffset="57-60" id="HPRD50.d21.s1.e1" origId="12" text="CB1" type="pm0109721" />      <entity charOffset="100-104" id="HPRD50.d21.s1.e2" origId="19" text="OX1R" type="pm0111533" />    </sentence>    <sentence charOffset="260-428" id="HPRD50.d21.s2" origId="12690115.2.5" text="In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers">      <entity charOffset="59-62" id="HPRD50.d21.s2.e0" origId="9" text="CB1" type="pm0109721" />      <entity charOffset="67-71" id="HPRD50.d21.s2.e1" origId="11" text="OX1R" type="pm0111533" />    </sentence>  </document>  <document id="HPRD50.d22" origId="12819203" set="train">    <sentence charOffset="0-99" id="HPRD50.d22.s0" origId="12819203.1.1" text="GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2">      <entity charOffset="0-6" id="HPRD50.d22.s0.e0" origId="1" text="GC-GAP" type="pm0122639" />      <entity charOffset="21-46" id="HPRD50.d22.s0.e1" origId="7" text="GTPase-activating protein" type="pm0112603" />      <entity charOffset="86-90" id="HPRD50.d22.s0.e2" origId="13" text="Gab1" type="pm0112697" />      <entity charOffset="95-99" id="HPRD50.d22.s0.e3" origId="15" text="Gab2" type="pm0111574" />      <interaction e1="HPRD50.d22.s0.e0" e2="HPRD50.d22.s0.e2" id="HPRD50.d22.s0.i0" type="PPI" />      <interaction e1="HPRD50.d22.s0.e0" e2="HPRD50.d22.s0.e3" id="HPRD50.d22.s0.i1" type="PPI" />      <interaction e1="HPRD50.d22.s0.e1" e2="HPRD50.d22.s0.e2" id="HPRD50.d22.s0.i2" type="PPI" />      <interaction e1="HPRD50.d22.s0.e1" e2="HPRD50.d22.s0.e3" id="HPRD50.d22.s0.i3" type="PPI" />    </sentence>    <sentence charOffset="100-309" id="HPRD50.d22.s1" origId="12819203.2.1" text="Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk">      <entity charOffset="0-4" id="HPRD50.d22.s1.e0" origId="1" text="Gab1" type="pm0112697" />      <entity charOffset="9-13" id="HPRD50.d22.s1.e1" origId="3" text="Gab2" type="pm0111574" />      <entity charOffset="153-157" id="HPRD50.d22.s1.e2" origId="24" text="Grb2" type="pm0105419" />      <entity charOffset="159-164" id="HPRD50.d22.s1.e3" origId="26" text="Shp-2" type="pm0122382" />      <entity charOffset="166-195" id="HPRD50.d22.s1.e4" origId="29" text="phosphatidylinositol 3-kinase" type="pm0104655||pm0110290||pm0120114||pm0122783||pm0124741" />      <interaction e1="HPRD50.d22.s1.e0" e2="HPRD50.d22.s1.e2" id="HPRD50.d22.s1.i0" type="PPI" />      <interaction e1="HPRD50.d22.s1.e0" e2="HPRD50.d22.s1.e3" id="HPRD50.d22.s1.i1" type="PPI" />      <interaction e1="HPRD50.d22.s1.e0" e2="HPRD50.d22.s1.e4" id="HPRD50.d22.s1.i2" type="PPI" />      <interaction e1="HPRD50.d22.s1.e1" e2="HPRD50.d22.s1.e2" id="HPRD50.d22.s1.i3" type="PPI" />      <interaction e1="HPRD50.d22.s1.e1" e2="HPRD50.d22.s1.e3" id="HPRD50.d22.s1.i4" type="PPI" />      <interaction e1="HPRD50.d22.s1.e1" e2="HPRD50.d22.s1.e4" id="HPRD50.d22.s1.i5" type="PPI" />    </sentence>    <sentence charOffset="310-454" id="HPRD50.d22.s2" origId="12819203.2.10" text="In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro">      <entity charOffset="13-19" id="HPRD50.d22.s2.e0" origId="4" text="GC-GAP" type="pm0122639" />      <entity charOffset="132-135" id="HPRD50.d22.s2.e1" origId="23" text="Nck" type="pm0121922" />      <interaction e1="HPRD50.d22.s2.e0" e2="HPRD50.d22.s2.e1" id="HPRD50.d22.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="455-657" id="HPRD50.d22.s3" origId="12819203.2.11" text="We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities">      <entity charOffset="16-20" id="HPRD50.d22.s3.e0" origId="4" text="Gab1" type="pm0112697" />      <entity charOffset="25-29" id="HPRD50.d22.s3.e1" origId="6" text="Gab2" type="pm0111574" />      <entity charOffset="118-124" id="HPRD50.d22.s3.e2" origId="19" text="GC-GAP" type="pm0122639" />      <entity charOffset="186-191" id="HPRD50.d22.s3.e3" origId="30" text="Cdc42" type="pm0110789" />      <interaction e1="HPRD50.d22.s3.e0" e2="HPRD50.d22.s3.e2" id="HPRD50.d22.s3.i0" type="PPI" />      <interaction e1="HPRD50.d22.s3.e0" e2="HPRD50.d22.s3.e3" id="HPRD50.d22.s3.i1" type="PPI" />      <interaction e1="HPRD50.d22.s3.e1" e2="HPRD50.d22.s3.e2" id="HPRD50.d22.s3.i2" type="PPI" />      <interaction e1="HPRD50.d22.s3.e1" e2="HPRD50.d22.s3.e3" id="HPRD50.d22.s3.i3" type="PPI" />    </sentence>    <sentence charOffset="658-755" id="HPRD50.d22.s4" origId="12819203.2.3" text="This work led to identification of a novel GTPase-activating protein (GAP) for Rho family GTPases">      <entity charOffset="43-68" id="HPRD50.d22.s4.e0" origId="10" text="GTPase-activating protein" type="pm0112603" />      <entity charOffset="70-73" id="HPRD50.d22.s4.e1" origId="12" text="GAP" type="pm0112603||pm0113293" />    </sentence>    <sentence charOffset="756-881" id="HPRD50.d22.s5" origId="12819203.2.4" text="The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro">      <entity charOffset="60-65" id="HPRD50.d22.s5.e0" origId="11" text="CdGAP" type="pm0102116" />      <entity charOffset="101-105" id="HPRD50.d22.s5.e1" origId="18" text="Rac1" type="pm0109115" />      <entity charOffset="111-116" id="HPRD50.d22.s5.e2" origId="21" text="Cdc42" type="pm0110789" />    </sentence>    <sentence charOffset="882-994" id="HPRD50.d22.s6" origId="12819203.2.5" text="The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42">      <entity charOffset="22-28" id="HPRD50.d22.s6.e0" origId="5" text="GC-GAP" type="pm0122639" />      <entity charOffset="62-65" id="HPRD50.d22.s6.e1" origId="12" text="GAB" type="pm0100534" />      <entity charOffset="107-112" id="HPRD50.d22.s6.e2" origId="20" text="Cdc42" type="pm0110789" />      <interaction e1="HPRD50.d22.s6.e0" e2="HPRD50.d22.s6.e1" id="HPRD50.d22.s6.i0" type="PPI" />      <interaction e1="HPRD50.d22.s6.e0" e2="HPRD50.d22.s6.e2" id="HPRD50.d22.s6.i1" type="PPI" />    </sentence>    <sentence charOffset="995-1093" id="HPRD50.d22.s7" origId="12819203.2.8" text="Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA">      <entity charOffset="14-20" id="HPRD50.d22.s7.e0" origId="3" text="GC-GAP" type="pm0122639" />      <entity charOffset="64-68" id="HPRD50.d22.s7.e1" origId="13" text="Rac1" type="pm0109115" />      <entity charOffset="73-78" id="HPRD50.d22.s7.e2" origId="15" text="Cdc42" type="pm0110789" />      <interaction e1="HPRD50.d22.s7.e0" e2="HPRD50.d22.s7.e1" id="HPRD50.d22.s7.i0" type="PPI" />      <interaction e1="HPRD50.d22.s7.e0" e2="HPRD50.d22.s7.e2" id="HPRD50.d22.s7.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d23" origId="12852857" set="train">    <sentence charOffset="0-54" id="HPRD50.d23.s0" origId="12852857.1.1" text="A role for Plk1 phosphorylation of NudC in cytokinesis">      <entity charOffset="11-15" id="HPRD50.d23.s0.e0" origId="4" text="Plk1" type="pm0109061" />      <entity charOffset="35-39" id="HPRD50.d23.s0.e1" origId="7" text="NudC" type="pm0116104" />      <interaction e1="HPRD50.d23.s0.e0" e2="HPRD50.d23.s0.e1" id="HPRD50.d23.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="55-264" id="HPRD50.d23.s1" origId="12852857.2.3" text="Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo">      <entity charOffset="46-50" id="HPRD50.d23.s1.e0" origId="8" text="Plk1" type="pm0109061" />      <entity charOffset="55-59" id="HPRD50.d23.s1.e1" origId="10" text="NudC" type="pm0116104" />      <entity charOffset="71-75" id="HPRD50.d23.s1.e2" origId="14" text="Plk1" type="pm0109061" />      <entity charOffset="91-95" id="HPRD50.d23.s1.e3" origId="16" text="NudC" type="pm0116104" />      <entity charOffset="168-172" id="HPRD50.d23.s1.e4" origId="30" text="NudC" type="pm0116104" />      <entity charOffset="197-201" id="HPRD50.d23.s1.e5" origId="36" text="Plk1" type="pm0109061" />      <interaction e1="HPRD50.d23.s1.e0" e2="HPRD50.d23.s1.e1" id="HPRD50.d23.s1.i0" type="PPI" />      <interaction e1="HPRD50.d23.s1.e2" e2="HPRD50.d23.s1.e3" id="HPRD50.d23.s1.i1" type="PPI" />      <interaction e1="HPRD50.d23.s1.e4" e2="HPRD50.d23.s1.e5" id="HPRD50.d23.s1.i2" type="PPI" />    </sentence>    <sentence charOffset="265-535" id="HPRD50.d23.s2" origId="12852857.2.4" text="Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites">      <entity charOffset="18-22" id="HPRD50.d23.s2.e0" origId="3" text="NudC" type="pm0116104" />      <entity charOffset="200-204" id="HPRD50.d23.s2.e1" origId="31" text="NudC" type="pm0116104" />      <entity charOffset="217-221" id="HPRD50.d23.s2.e2" origId="36" text="NudC" type="pm0116104" />      <entity charOffset="244-248" id="HPRD50.d23.s2.e3" origId="41" text="Plk1" type="pm0109061" />    </sentence>    <sentence charOffset="536-617" id="HPRD50.d23.s3" origId="12852857.2.5" text="These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis">      <entity charOffset="27-31" id="HPRD50.d23.s3.e0" origId="5" text="Plk1" type="pm0109061" />      <entity charOffset="51-55" id="HPRD50.d23.s3.e1" origId="8" text="NudC" type="pm0116104" />      <interaction e1="HPRD50.d23.s3.e0" e2="HPRD50.d23.s3.e1" id="HPRD50.d23.s3.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d24" origId="12947119" set="train">    <sentence charOffset="0-133" id="HPRD50.d24.s0" origId="12947119.1.1" text="Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene">      <entity charOffset="24-28" id="HPRD50.d24.s0.e0" origId="4" text="Egr1" type="pm0115655" />      <entity charOffset="96-128" id="HPRD50.d24.s0.e1" origId="20" text="low density lipoprotein receptor" type="pm0125757" />      <interaction e1="HPRD50.d24.s0.e0" e2="HPRD50.d24.s0.e1" id="HPRD50.d24.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="134-326" id="HPRD50.d24.s1" origId="12947119.2.1" text="The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway">      <entity charOffset="56-68" id="HPRD50.d24.s1.e0" origId="11" text="LDL receptor" type="pm0125757" />      <entity charOffset="70-74" id="HPRD50.d24.s1.e1" origId="13" text="LDLR" type="pm0125757" />      <entity charOffset="94-106" id="HPRD50.d24.s1.e2" origId="18" text="oncostatin M" type="pm0100359" />      <entity charOffset="141-145" id="HPRD50.d24.s1.e3" origId="26" text="LDLR" type="pm0125757" />      <interaction e1="HPRD50.d24.s1.e0" e2="HPRD50.d24.s1.e2" id="HPRD50.d24.s1.i0" type="PPI" />      <interaction e1="HPRD50.d24.s1.e1" e2="HPRD50.d24.s1.e2" id="HPRD50.d24.s1.i1" type="PPI" />      <interaction e1="HPRD50.d24.s1.e2" e2="HPRD50.d24.s1.e3" id="HPRD50.d24.s1.i2" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d25" origId="12949936" set="train">    <sentence charOffset="0-103" id="HPRD50.d25.s0" origId="12949936.1.1" text="TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3">      <entity charOffset="0-3" id="HPRD50.d25.s0.e0" origId="1" text="TR2" type="pm0104071||pm0107975||pm0108440||pm0116348||pm0122716" />      <entity charOffset="56-73" id="HPRD50.d25.s0.e1" origId="10" text="androgen receptor" type="pm0125088" />      <entity charOffset="99-103" id="HPRD50.d25.s0.e2" origId="15" text="PC-3" type="pm0107379||pm0107715||pm0114827" />      <interaction e1="HPRD50.d25.s0.e0" e2="HPRD50.d25.s0.e1" id="HPRD50.d25.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="104-283" id="HPRD50.d25.s1" origId="12949936.2.1" text="BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines">      <entity charOffset="17-34" id="HPRD50.d25.s1.e0" origId="5" text="androgen receptor" type="pm0125088" />      <entity charOffset="60-63" id="HPRD50.d25.s1.e1" origId="12" text="TR2" type="pm0104071||pm0107975||pm0108440||pm0116348||pm0122716" />      <entity charOffset="65-68" id="HPRD50.d25.s1.e2" origId="14" text="TR2" type="pm0104071||pm0107975||pm0108440||pm0116348||pm0122716" />    </sentence>    <sentence charOffset="284-420" id="HPRD50.d25.s2" origId="12949936.2.7" text="The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay">      <entity charOffset="31-34" id="HPRD50.d25.s2.e0" origId="6" text="TR2" type="pm0104071||pm0107975||pm0108440||pm0116348||pm0122716" />      <entity charOffset="51-76" id="HPRD50.d25.s2.e1" origId="10" text="glutathione-S-transferase" type="pm0116848" />      <entity charOffset="78-81" id="HPRD50.d25.s2.e2" origId="12" text="GST" type="pm0116848" />    </sentence>  </document>  <document id="HPRD50.d26" origId="14556007" set="train">    <sentence charOffset="0-176" id="HPRD50.d26.s0" origId="14556007.2.2" text="The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1 alpha for proteasomal degradation during normoxia">      <entity charOffset="12-16" id="HPRD50.d26.s0.e0" origId="3" text="pVHL" type="pm0104236" />      <entity charOffset="122-132" id="HPRD50.d26.s0.e1" origId="18" text="Hif1 alpha" type="pm0100197" />      <interaction e1="HPRD50.d26.s0.e0" e2="HPRD50.d26.s0.e1" id="HPRD50.d26.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="177-299" id="HPRD50.d26.s1" origId="14556007.2.3" text="We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome">      <entity charOffset="18-22" id="HPRD50.d26.s1.e0" origId="4" text="pVHL" type="pm0104236" />      <entity charOffset="32-53" id="HPRD50.d26.s1.e1" origId="8" text="Tat-binding protein-1" type="pm0113245" />      <entity charOffset="55-60" id="HPRD50.d26.s1.e2" origId="10" text="TBP-1" type="pm0113245||pm0120764" />      <interaction e1="HPRD50.d26.s1.e0" e2="HPRD50.d26.s1.e1" id="HPRD50.d26.s1.i0" type="PPI" />      <interaction e1="HPRD50.d26.s1.e0" e2="HPRD50.d26.s1.e2" id="HPRD50.d26.s1.i1" type="PPI" />    </sentence>    <sentence charOffset="300-392" id="HPRD50.d26.s2" origId="14556007.2.4" text="TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo">      <entity charOffset="0-5" id="HPRD50.d26.s2.e0" origId="1" text="TBP-1" type="pm0113245||pm0120764" />      <entity charOffset="41-45" id="HPRD50.d26.s2.e1" origId="7" text="pVHL" type="pm0104236" />      <entity charOffset="65-69" id="HPRD50.d26.s2.e2" origId="11" text="pVHL" type="pm0104236" />      <entity charOffset="74-84" id="HPRD50.d26.s2.e3" origId="14" text="Hif1 alpha" type="pm0100197" />      <interaction e1="HPRD50.d26.s2.e0" e2="HPRD50.d26.s2.e1" id="HPRD50.d26.s2.i0" type="PPI" />      <interaction e1="HPRD50.d26.s2.e0" e2="HPRD50.d26.s2.e2" id="HPRD50.d26.s2.i1" type="PPI" />      <interaction e1="HPRD50.d26.s2.e0" e2="HPRD50.d26.s2.e3" id="HPRD50.d26.s2.i2" type="PPI" />    </sentence>    <sentence charOffset="393-519" id="HPRD50.d26.s3" origId="14556007.2.5" text="Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1">      <entity charOffset="18-23" id="HPRD50.d26.s3.e0" origId="3" text="TBP-1" type="pm0113245||pm0120764" />      <entity charOffset="48-58" id="HPRD50.d26.s3.e1" origId="8" text="Hif1 alpha" type="pm0100197" />      <entity charOffset="121-126" id="HPRD50.d26.s3.e2" origId="19" text="TBP-1" type="pm0113245||pm0120764" />      <interaction e1="HPRD50.d26.s3.e0" e2="HPRD50.d26.s3.e1" id="HPRD50.d26.s3.i0" type="PPI" />      <interaction e1="HPRD50.d26.s3.e1" e2="HPRD50.d26.s3.e2" id="HPRD50.d26.s3.i1" type="PPI" />    </sentence>    <sentence charOffset="520-633" id="HPRD50.d26.s4" origId="14556007.2.6" text="Blockade of TBP-1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Hif1 alpha">      <entity charOffset="12-17" id="HPRD50.d26.s4.e0" origId="3" text="TBP-1" type="pm0113245||pm0120764" />      <entity charOffset="103-113" id="HPRD50.d26.s4.e1" origId="18" text="Hif1 alpha" type="pm0100197" />      <interaction e1="HPRD50.d26.s4.e0" e2="HPRD50.d26.s4.e1" id="HPRD50.d26.s4.i0" type="PPI" />    </sentence>    <sentence charOffset="634-710" id="HPRD50.d26.s5" origId="14556007.2.7" text="Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1">      <entity charOffset="40-43" id="HPRD50.d26.s5.e0" origId="8" text="VHL" type="pm0104236" />      <entity charOffset="63-67" id="HPRD50.d26.s5.e1" origId="12" text="pVHL" type="pm0104236" />      <entity charOffset="71-76" id="HPRD50.d26.s5.e2" origId="14" text="TBP-1" type="pm0113245||pm0120764" />      <interaction e1="HPRD50.d26.s5.e0" e2="HPRD50.d26.s5.e2" id="HPRD50.d26.s5.i0" type="PPI" />      <interaction e1="HPRD50.d26.s5.e1" e2="HPRD50.d26.s5.e2" id="HPRD50.d26.s5.i1" type="PPI" />    </sentence>    <sentence charOffset="711-856" id="HPRD50.d26.s6" origId="14556007.2.8" text="A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha">      <entity charOffset="2-6" id="HPRD50.d26.s6.e0" origId="2" text="pVHL" type="pm0104236" />      <entity charOffset="72-82" id="HPRD50.d26.s6.e1" origId="11" text="Hif1 alpha" type="pm0100197" />      <entity charOffset="92-97" id="HPRD50.d26.s6.e2" origId="15" text="TBP-1" type="pm0113245||pm0120764" />      <entity charOffset="135-145" id="HPRD50.d26.s6.e3" origId="24" text="Hif1 alpha" type="pm0100197" />      <interaction e1="HPRD50.d26.s6.e0" e2="HPRD50.d26.s6.e1" id="HPRD50.d26.s6.i0" type="PPI" />    </sentence>    <sentence charOffset="857-1038" id="HPRD50.d26.s7" origId="14556007.2.9" text="Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors">      <entity charOffset="21-25" id="HPRD50.d26.s7.e0" origId="6" text="pVHL" type="pm0104236" />      <entity charOffset="37-47" id="HPRD50.d26.s7.e1" origId="10" text="Hif1 alpha" type="pm0100197" />      <entity charOffset="88-93" id="HPRD50.d26.s7.e2" origId="18" text="TBP-1" type="pm0113245||pm0120764" />      <entity charOffset="127-137" id="HPRD50.d26.s7.e3" origId="26" text="Hif1 alpha" type="pm0100197" />      <entity charOffset="160-164" id="HPRD50.d26.s7.e4" origId="30" text="pVHL" type="pm0104236" />      <interaction e1="HPRD50.d26.s7.e0" e2="HPRD50.d26.s7.e1" id="HPRD50.d26.s7.i0" type="PPI" />      <interaction e1="HPRD50.d26.s7.e0" e2="HPRD50.d26.s7.e2" id="HPRD50.d26.s7.i1" type="PPI" />      <interaction e1="HPRD50.d26.s7.e3" e2="HPRD50.d26.s7.e4" id="HPRD50.d26.s7.i2" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d27" origId="14578391" set="train">    <sentence charOffset="0-83" id="HPRD50.d27.s0" origId="14578391.1.1" text="Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells">      <entity charOffset="0-5" id="HPRD50.d27.s0.e0" origId="1" text="Pinin" type="pm0118763" />      <entity charOffset="6-9" id="HPRD50.d27.s0.e1" origId="3" text="DRS" type="pm0118763" />      <entity charOffset="30-35" id="HPRD50.d27.s0.e2" origId="8" text="SRp75" type="pm0111657" />      <entity charOffset="37-43" id="HPRD50.d27.s0.e3" origId="10" text="SRm300" type="pm0117461" />      <interaction e1="HPRD50.d27.s0.e0" e2="HPRD50.d27.s0.e2" id="HPRD50.d27.s0.i0" type="PPI" />      <interaction e1="HPRD50.d27.s0.e0" e2="HPRD50.d27.s0.e3" id="HPRD50.d27.s0.i1" type="PPI" />      <interaction e1="HPRD50.d27.s0.e1" e2="HPRD50.d27.s0.e2" id="HPRD50.d27.s0.i2" type="PPI" />      <interaction e1="HPRD50.d27.s0.e1" e2="HPRD50.d27.s0.e3" id="HPRD50.d27.s0.i3" type="PPI" />    </sentence>    <sentence charOffset="84-270" id="HPRD50.d27.s1" origId="14578391.2.8" text="Three SR-rich proteins were identified that interact with the C-terminus of Pnn: SRp75 and SRm300, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130">      <entity charOffset="81-86" id="HPRD50.d27.s1.e0" origId="14" text="SRp75" type="pm0111657" />      <entity charOffset="91-97" id="HPRD50.d27.s1.e1" origId="16" text="SRm300" type="pm0117461" />    </sentence>  </document>  <document id="HPRD50.d29" origId="14752048" set="train">    <sentence charOffset="0-169" id="HPRD50.d29.s0" origId="14752048.1.1" text="Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription">      <entity charOffset="50-56" id="HPRD50.d29.s0.e0" origId="9" text="Dnmt3a" type="pm0106301" />      <entity charOffset="61-67" id="HPRD50.d29.s0.e1" origId="12" text="SUMO-1" type="pm0108344" />      <interaction e1="HPRD50.d29.s0.e0" e2="HPRD50.d29.s0.e1" id="HPRD50.d29.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="170-467" id="HPRD50.d29.s1" origId="14752048.2.3" text="Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins">      <entity charOffset="18-24" id="HPRD50.d29.s1.e0" origId="5" text="Dnmt3a" type="pm0106301" />      <entity charOffset="128-132" id="HPRD50.d29.s1.e1" origId="21" text="Ubc9" type="pm0110323" />      <entity charOffset="157-162" id="HPRD50.d29.s1.e2" origId="27" text="PIAS1" type="pm0117395" />      <entity charOffset="167-177" id="HPRD50.d29.s1.e3" origId="29" text="PIASxalpha" type="pm0119764" />      <entity charOffset="267-273" id="HPRD50.d29.s1.e4" origId="44" text="SUMO-1" type="pm0108344" />      <interaction e1="HPRD50.d29.s1.e0" e2="HPRD50.d29.s1.e1" id="HPRD50.d29.s1.i0" type="PPI" />      <interaction e1="HPRD50.d29.s1.e0" e2="HPRD50.d29.s1.e2" id="HPRD50.d29.s1.i1" type="PPI" />      <interaction e1="HPRD50.d29.s1.e0" e2="HPRD50.d29.s1.e3" id="HPRD50.d29.s1.i2" type="PPI" />      <interaction e1="HPRD50.d29.s1.e1" e2="HPRD50.d29.s1.e4" id="HPRD50.d29.s1.i3" type="PPI" />      <interaction e1="HPRD50.d29.s1.e2" e2="HPRD50.d29.s1.e4" id="HPRD50.d29.s1.i4" type="PPI" />      <interaction e1="HPRD50.d29.s1.e3" e2="HPRD50.d29.s1.e4" id="HPRD50.d29.s1.i5" type="PPI" />    </sentence>    <sentence charOffset="468-611" id="HPRD50.d29.s2" origId="14752048.2.4" text="Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain">      <entity charOffset="0-6" id="HPRD50.d29.s2.e0" origId="1" text="Dnmt3a" type="pm0106301" />      <entity charOffset="22-28" id="HPRD50.d29.s2.e1" origId="5" text="SUMO-1" type="pm0108344" />      <entity charOffset="68-74" id="HPRD50.d29.s2.e2" origId="15" text="Dnmt3a" type="pm0106301" />      <interaction e1="HPRD50.d29.s2.e0" e2="HPRD50.d29.s2.e1" id="HPRD50.d29.s2.i0" type="PPI" />    </sentence>    <sentence charOffset="612-766" id="HPRD50.d29.s3" origId="14752048.2.5" text="Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b">      <entity charOffset="29-35" id="HPRD50.d29.s3.e0" origId="5" text="Dnmt3a" type="pm0106301" />      <entity charOffset="96-101" id="HPRD50.d29.s3.e1" origId="15" text="HDAC1" type="pm0119729" />      <entity charOffset="148-154" id="HPRD50.d29.s3.e2" origId="27" text="Dnmt3b" type="pm0126533" />      <interaction e1="HPRD50.d29.s3.e0" e2="HPRD50.d29.s3.e1" id="HPRD50.d29.s3.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d30" origId="7629131" set="train">    <sentence charOffset="0-154" id="HPRD50.d30.s0" origId="7629131.2.1" text="The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation">      <entity charOffset="20-25" id="HPRD50.d30.s0.e0" origId="4" text="Tyk-2" type="pm0101504" />      <entity charOffset="79-82" id="HPRD50.d30.s0.e1" origId="14" text="IFN" type="pm0111853" />      <entity charOffset="133-142" id="HPRD50.d30.s0.e2" origId="24" text="IFN alpha" type="pm0111853" />      <interaction e1="HPRD50.d30.s0.e0" e2="HPRD50.d30.s0.e1" id="HPRD50.d30.s0.i0" type="PPI" />      <interaction e1="HPRD50.d30.s0.e0" e2="HPRD50.d30.s0.e2" id="HPRD50.d30.s0.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d31" origId="7744247" set="train">    <sentence charOffset="0-99" id="HPRD50.d31.s0" origId="7744247.1.1" text="Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation">      <entity charOffset="0-4" id="HPRD50.d31.s0.e0" origId="1" text="Raf1" type="pm0117803" />      <entity charOffset="22-27" id="HPRD50.d31.s0.e1" origId="4" text="Cdc25" type="pm0106635||pm0109000" />      <interaction e1="HPRD50.d31.s0.e0" e2="HPRD50.d31.s0.e1" id="HPRD50.d31.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="100-211" id="HPRD50.d31.s1" origId="7744247.2.3" text="We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes">      <entity charOffset="18-23" id="HPRD50.d31.s1.e0" origId="5" text="Cdc25" type="pm0106635||pm0109000" />      <entity charOffset="52-56" id="HPRD50.d31.s1.e1" origId="9" text="raf1" type="pm0117803" />      <interaction e1="HPRD50.d31.s1.e0" e2="HPRD50.d31.s1.e1" id="HPRD50.d31.s1.i0" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d32" origId="7793988" set="train">    <sentence charOffset="0-154" id="HPRD50.d32.s0" origId="7793988.1.1" text="Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease">      <entity charOffset="61-69" id="HPRD50.d32.s0.e0" origId="8" text="perlecan" type="pm0116983" />      <entity charOffset="71-79" id="HPRD50.d32.s0.e1" origId="10" text="biglycan" type="pm0124379" />      <entity charOffset="81-88" id="HPRD50.d32.s0.e2" origId="12" text="decorin" type="pm0108608" />      <entity charOffset="94-102" id="HPRD50.d32.s0.e3" origId="15" text="versican" type="pm0106611" />    </sentence>    <sentence charOffset="155-430" id="HPRD50.d32.s1" origId="7793988.2.1" text="Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain">      <entity charOffset="61-69" id="HPRD50.d32.s1.e0" origId="8" text="perlecan" type="pm0116983" />      <entity charOffset="82-110" id="HPRD50.d32.s1.e1" origId="14" text="heparan sulfate proteoglycan" type="pm0112250" />      <entity charOffset="119-131" id="HPRD50.d32.s1.e2" origId="18" text="beta-amyloid" type="beta-pm0104696" />      <entity charOffset="160-167" id="HPRD50.d32.s1.e3" origId="25" text="amyloid" type="pm0104696" />      <interaction e1="HPRD50.d32.s1.e0" e2="HPRD50.d32.s1.e2" id="HPRD50.d32.s1.i0" type="PPI" />      <interaction e1="HPRD50.d32.s1.e0" e2="HPRD50.d32.s1.e3" id="HPRD50.d32.s1.i1" type="PPI" />      <interaction e1="HPRD50.d32.s1.e1" e2="HPRD50.d32.s1.e2" id="HPRD50.d32.s1.i2" type="PPI" />      <interaction e1="HPRD50.d32.s1.e1" e2="HPRD50.d32.s1.e3" id="HPRD50.d32.s1.i3" type="PPI" />    </sentence>    <sentence charOffset="431-688" id="HPRD50.d32.s2" origId="7793988.2.10" text="Overall, the results indicate that specific vascular cell-derived PGs differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of perlecan">      <entity charOffset="66-69" id="HPRD50.d32.s2.e0" origId="10" text="PGs" type="pm0108066" />      <entity charOffset="249-257" id="HPRD50.d32.s2.e1" origId="40" text="perlecan" type="pm0116983" />    </sentence>    <sentence charOffset="689-987" id="HPRD50.d32.s3" origId="7793988.2.2" text="In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan">      <entity charOffset="130-133" id="HPRD50.d32.s3.e0" origId="23" text="SMC" type="pm0101876" />      <entity charOffset="143-146" id="HPRD50.d32.s3.e1" origId="26" text="PGs" type="pm0108066" />      <entity charOffset="237-244" id="HPRD50.d32.s3.e2" origId="42" text="amyloid" type="pm0104696" />      <entity charOffset="290-298" id="HPRD50.d32.s3.e3" origId="51" text="perlecan" type="pm0116983" />    </sentence>    <sentence charOffset="988-1270" id="HPRD50.d32.s4" origId="7793988.2.3" text="Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase">      <entity charOffset="178-186" id="HPRD50.d32.s4.e0" origId="29" text="perlecan" type="pm0116983" />      <entity charOffset="273-276" id="HPRD50.d32.s4.e1" origId="43" text="ABC" type="pm0102466" />    </sentence>    <sentence charOffset="1271-1537" id="HPRD50.d32.s5" origId="7793988.2.4" text="[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin">      <entity charOffset="37-40" id="HPRD50.d32.s5.e0" origId="8" text="PGs" type="pm0108066" />      <entity charOffset="253-266" id="HPRD50.d32.s5.e1" origId="56" text="serum albumin" type="pm0103143" />    </sentence>    <sentence charOffset="1538-1785" id="HPRD50.d32.s6" origId="7793988.2.5" text="Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan">      <entity charOffset="27-30" id="HPRD50.d32.s6.e0" origId="5" text="SMC" type="pm0101876" />      <entity charOffset="31-34" id="HPRD50.d32.s6.e1" origId="6" text="PGs" type="pm0108066" />      <entity charOffset="85-93" id="HPRD50.d32.s6.e2" origId="18" text="perlecan" type="pm0116983" />      <entity charOffset="111-118" id="HPRD50.d32.s6.e3" origId="23" text="decorin" type="pm0108608" />      <entity charOffset="123-131" id="HPRD50.d32.s6.e4" origId="25" text="biglycan" type="pm0124379" />      <entity charOffset="192-200" id="HPRD50.d32.s6.e5" origId="37" text="versican" type="pm0106611" />      <entity charOffset="201-205" id="HPRD50.d32.s6.e6" origId="39" text="PG-M" type="pm0106611" />      <interaction e1="HPRD50.d32.s6.e1" e2="HPRD50.d32.s6.e2" id="HPRD50.d32.s6.i0" type="PPI" />      <interaction e1="HPRD50.d32.s6.e1" e2="HPRD50.d32.s6.e3" id="HPRD50.d32.s6.i1" type="PPI" />      <interaction e1="HPRD50.d32.s6.e1" e2="HPRD50.d32.s6.e4" id="HPRD50.d32.s6.i2" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d33" origId="7963560" set="train">    <sentence charOffset="0-347" id="HPRD50.d33.s0" origId="7963560.2.5" text="Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D">      <entity charOffset="17-21" id="HPRD50.d33.s0.e0" origId="3" text="CD53" type="pm0107494" />      <entity charOffset="226-230" id="HPRD50.d33.s0.e1" origId="41" text="CD69" type="pm0115739" />      <entity charOffset="281-286" id="HPRD50.d33.s0.e2" origId="52" text="c-myc" type="pm0104123" />      <interaction e1="HPRD50.d33.s0.e0" e2="HPRD50.d33.s0.e1" id="HPRD50.d33.s0.i0" type="PPI" />      <interaction e1="HPRD50.d33.s0.e0" e2="HPRD50.d33.s0.e2" id="HPRD50.d33.s0.i1" type="PPI" />    </sentence>    <sentence charOffset="348-459" id="HPRD50.d33.s1" origId="7963560.2.8" text="However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53">      <entity charOffset="34-38" id="HPRD50.d33.s1.e0" origId="7" text="IL-2" type="pm0110478" />      <entity charOffset="43-47" id="HPRD50.d33.s1.e1" origId="9" text="IL-4" type="pm0106845" />      <entity charOffset="107-111" id="HPRD50.d33.s1.e2" origId="19" text="CD53" type="pm0107494" />      <interaction e1="HPRD50.d33.s1.e0" e2="HPRD50.d33.s1.e2" id="HPRD50.d33.s1.i0" type="PPI" />      <interaction e1="HPRD50.d33.s1.e1" e2="HPRD50.d33.s1.e2" id="HPRD50.d33.s1.i1" type="PPI" />    </sentence>  </document>  <document id="HPRD50.d34" origId="8078915" set="train">    <sentence charOffset="0-156" id="HPRD50.d34.s0" origId="8078915.2.11" text="The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases">      <entity charOffset="10-14" id="HPRD50.d34.s0.e0" origId="3" text="apoB" type="pm0126272" />      <entity charOffset="41-59" id="HPRD50.d34.s0.e1" origId="10" text="cytidine deaminase" type="pm0107865" />    </sentence>    <sentence charOffset="157-303" id="HPRD50.d34.s1" origId="8078915.2.13" text="The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans">      <entity charOffset="18-22" id="HPRD50.d34.s1.e0" origId="5" text="apoB" type="pm0126272" />      <entity charOffset="61-70" id="HPRD50.d34.s1.e1" origId="13" text="homodimer" type="pm0125626" />      <entity charOffset="119-123" id="HPRD50.d34.s1.e2" origId="21" text="apoB" type="pm0126272" />    </sentence>  </document>  <document id="HPRD50.d35" origId="8617498" set="train">    <sentence charOffset="0-143" id="HPRD50.d35.s0" origId="8617498.1.1" text="Assignment of Etfdh, Etfb, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human">      <entity charOffset="14-19" id="HPRD50.d35.s0.e0" origId="3" text="Etfdh" type="pm0103481" />      <entity charOffset="21-25" id="HPRD50.d35.s0.e1" origId="5" text="Etfb" type="pm0110405" />    </sentence>    <sentence charOffset="144-274" id="HPRD50.d35.s1" origId="8617498.2.4" text="We used cDNA probes for the Etfdh, Etfb, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13">      <entity charOffset="28-33" id="HPRD50.d35.s1.e0" origId="7" text="Etfdh" type="pm0103481" />      <entity charOffset="35-39" id="HPRD50.d35.s1.e1" origId="9" text="Etfb" type="pm0110405" />    </sentence>  </document>  <document id="HPRD50.d38" origId="8999895" set="train">    <sentence charOffset="0-329" id="HPRD50.d38.s0" origId="8999895.2.6" text="Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family">      <entity charOffset="66-76" id="HPRD50.d38.s0.e0" origId="9" text="involucrin" type="pm0104308" />      <entity charOffset="171-185" id="HPRD50.d38.s0.e1" origId="27" text="cystatin alpha" type="pm0104526" />      <entity charOffset="187-198" id="HPRD50.d38.s0.e2" origId="29" text="desmoplakin" type="pm0110549" />      <entity charOffset="200-206" id="HPRD50.d38.s0.e3" origId="31" text="elafin" type="pm0114270" />      <entity charOffset="265-273" id="HPRD50.d38.s0.e4" origId="42" text="loricrin" type="pm0103809" />      <entity charOffset="311-322" id="HPRD50.d38.s0.e5" origId="50" text="desmoplakin" type="pm0110549" />      <interaction e1="HPRD50.d38.s0.e0" e2="HPRD50.d38.s0.e1" id="HPRD50.d38.s0.i0" type="PPI" />      <interaction e1="HPRD50.d38.s0.e0" e2="HPRD50.d38.s0.e2" id="HPRD50.d38.s0.i1" type="PPI" />      <interaction e1="HPRD50.d38.s0.e0" e2="HPRD50.d38.s0.e3" id="HPRD50.d38.s0.i2" type="PPI" />      <interaction e1="HPRD50.d38.s0.e0" e2="HPRD50.d38.s0.e4" id="HPRD50.d38.s0.i3" type="PPI" />      <interaction e1="HPRD50.d38.s0.e0" e2="HPRD50.d38.s0.e5" id="HPRD50.d38.s0.i4" type="PPI" />    </sentence>    <sentence charOffset="330-591" id="HPRD50.d38.s1" origId="8999895.2.7" text="Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links">      <entity charOffset="34-44" id="HPRD50.d38.s1.e0" origId="6" text="involucrin" type="pm0104308" />      <entity charOffset="127-138" id="HPRD50.d38.s1.e1" origId="22" text="desmoplakin" type="pm0110549" />      <entity charOffset="239-249" id="HPRD50.d38.s1.e2" origId="44" text="involucrin" type="pm0104308" />    </sentence>  </document>  <document id="HPRD50.d39" origId="9153302" set="train">    <sentence charOffset="0-116" id="HPRD50.d39.s0" origId="9153302.2.4" text="A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro">      <entity charOffset="32-37" id="HPRD50.d39.s0.e0" origId="6" text="SRcyp" type="pm0120029" />      <entity charOffset="38-44" id="HPRD50.d39.s0.e1" origId="8" text="CASP10" type="pm0122990" />      <entity charOffset="78-81" id="HPRD50.d39.s0.e2" origId="14" text="CTD" type="pm0113359" />      <interaction e1="HPRD50.d39.s0.e0" e2="HPRD50.d39.s0.e2" id="HPRD50.d39.s0.i0" type="PPI" />      <interaction e1="HPRD50.d39.s0.e1" e2="HPRD50.d39.s0.e2" id="HPRD50.d39.s0.i1" type="PPI" />    </sentence>    <sentence charOffset="117-301" id="HPRD50.d39.s1" origId="9153302.2.7" text="SRcyp is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing splicing factor SC35">      <entity charOffset="0-5" id="HPRD50.d39.s1.e0" origId="1" text="SRcyp" type="pm0120029" />      <entity charOffset="164-184" id="HPRD50.d39.s1.e1" origId="25" text="splicing factor SC35" type="pm0120690" />    </sentence>  </document>  <document id="HPRD50.d40" origId="9668116" set="train">    <sentence charOffset="0-139" id="HPRD50.d40.s0" origId="9668116.2.6" text="Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-1.B promoter activity">      <entity charOffset="40-44" id="HPRD50.d40.s0.e0" origId="6" text="E2-2" type="pm0110165" />      <entity charOffset="114-121" id="HPRD50.d40.s0.e1" origId="17" text="FGF-1.B" type="pm0124654-1.B" />      <interaction e1="HPRD50.d40.s0.e0" e2="HPRD50.d40.s0.e1" id="HPRD50.d40.s0.i0" type="PPI" />    </sentence>    <sentence charOffset="140-295" id="HPRD50.d40.s1" origId="9668116.2.9" text="These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1">      <entity charOffset="80-84" id="HPRD50.d40.s1.e0" origId="14" text="E2-2" type="pm0110165" />      <entity charOffset="150-155" id="HPRD50.d40.s1.e1" origId="26" text="FGF-1" type="pm0124654" />      <interaction e1="HPRD50.d40.s1.e0" e2="HPRD50.d40.s1.e1" id="HPRD50.d40.s1.i0" type="PPI" />    </sentence>  </document></corpus>